Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.15
- Piotroski Score 2.00
- Grade Sector Outperform
- Symbol (PACB)
- Company Pacific Biosciences of California, Inc.
- Price $1.82
- Changes Percentage (5.54%)
- Change $0.1
- Day Low $1.70
- Day High $1.84
- Year High $10.65
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $4.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.14
- Trailing P/E Ratio -1.76
- Forward P/E Ratio -1.76
- P/E Growth -1.76
- Net Income $-306,735,000
Income Statement
Quarterly
Annual
Latest News of PACB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Pacific Biosciences of California, Inc. (PACB) Stock Price, News, Quote & History
Pacific Biosciences of California (PacBio) will be presenting at investor conferences, including UBS Global Healthcare Conference on Nov 13, 2024, and Wolfe Research Healthcare Conference on Nov 19, 2...
By Yahoo! Finance | 1 week ago -
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology
A list of promising gene editing stocks includes Pacific Biosciences of California. The pharmaceutical industry sees innovation in gene therapy and editing, with CRISPR technology advancing into clini...
By Yahoo! Finance | 3 weeks ago -
Pacific Biosciences of California, Inc. (PACB): Among the Worst ARK Stocks According to Short Sellers
The article discusses Cathie Wood's ARK Investment strategy, focusing on disruptive innovation stocks. It highlights the performance of some top stocks and mentions Pacific Biosciences of California, ...
By Yahoo! Finance | 2 months ago
